Clinical trials: Independence
Prostate Cancer
Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer
The purpose of this study is to find out how effective 177Lu -J591 is in the treatment of patients with metastatic, androgen-independent prostate cancer.
- Trial name
- NCT00195039
- Testing
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
BAY 43-9006 (Sorafenib) is an experimental cancer drug produced by Bayer Health Care Corporation. It represents a new class of anticancer agents known as bi-aryl ureas.
- Trial name
- NCT00090545
- Testing
- BAY 43-9006
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Spinal Cord Injury Cervical
Access-H20 Faucet for Spinal Cord Injury
The Phase I SBIR objective is to design, develop \& demonstrate feasibility of Access-H2OTM, a sensor driven smart faucet to enable and empower independent drinking and grooming for individuals impacted by spinal cord injury…
- Trial name
- NCT06159946
- Testing
- Access-H2O faucet
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Old Dominion University
Traumatic Brain Injury, Post-Traumatic Stress Disorder
Executive Functioning in TBI From Rehabilitation to Social Reintegration: COMPASS
Interventional, controlled clinical trial with two arms, 110 Veterans with TBI and PTSD
- Trial name
- COMPASS (NCT01816061)
- Testing
- Experimental - COMPASS, Control - COMPASS
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Prostate Cancer
Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
This is a Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC).
- Trial name
- NCT00901342
- Testing
- sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 104 people
- Sponsor
- Dendreon
Alzheimer Disease, Dementia
Moving Together: An Online Group Movement Program for People Living With Memory Loss and Caregivers
To determine whether Moving Together improves quality of life in people with memory loss (PWML) and caregivers (CG) by performing a randomized, controlled trial (RCT) with a waitlist control group in 224 dyads.
- Trial name
- NCT04621448
- Testing
- Moving Together
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- University of California, San Francisco
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Multiple Trauma
Independent Predictors of Mortality in Polytrauma Patients
Prospective observational trial searching for independent predictors of mortality. Data was collected at trauma scene, ER, three and 24 hours of hospital stay.The patients will be followed for 30 days after hospital admission.
- Trial name
- NCT01669577
- Testing
- analysis of blood samples and clinical features
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- University of Sao Paulo
Cushing's Syndrome
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol.
- Trial name
- NCT02804750
- Testing
- CORT125134
- Where
- 25 sites in United States, Hungary and 3 more
- Volunteers
- 35 people
- Sponsor
- Corcept Therapeutics